YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities

Large cell neuroendocrine carcinoma (LCNEC) represents a high-grade pulmonary malignancy frequently characterized by aggressive progression and limited therapeutic options. Prior research has shown that this disease shares clinical similarities with small cell lung cancer (SCLC), including a lack of actionable oncogenic drivers and a generally dismal patient prognosis. Standard clinical management typically involves extrapolating treatment protocols from either small cell or non-small cell lung cancer frameworks due to a lack of disease-specific guidelines. While genomic profiling has identified common mutations in TP53 and RB1, the underlying biological heterogeneity of these tumors remains poorly understood. The absence of a robust molecular classification system prevents the development of precision medicine approaches tailored to the unique vulnerabilities of specific patient cohorts. Current diagnostic criteria often fail to capture the nuanced molecular differences that dictate how individual tumors respond to chemotherapy or immunotherapy. This absence of evidence motivated a comprehensive investigation into the intrinsic subtypes of this malignancy to identify biomarkers that could dictate more effective clinical interventions.

This investigation sought to define the biological landscape of large cell neuroendocrine carcinoma by identifying distinct molecular subsets through comprehensive genomic and transcriptomic analysis. Researchers focused on the expression of Yes-associated protein 1 (YAP1) as a potential master regulator of tumor phenotype and therapeutic response. The team intended to characterize the specific mutational profiles and immune microenvironments associated with different levels of this transcriptional coactivator. Identifying specific vulnerabilities in each subtype served as a primary objective to facilitate the development of targeted pharmacological and cellular therapies. The study also aimed to compare these subtypes with established small cell lung cancer models to determine if existing treatment paradigms are biologically justified. By utilizing high-resolution single-cell sequencing, the authors hoped to uncover the cellular diversity within core needle biopsies that traditional bulk sequencing might overlook. Establishing a clear link between transcriptional status and drug sensitivity was essential for proposing a new stratification framework for future clinical trials.

The research team integrated genomic data from established cell lines and diverse patient cohorts to identify recurrent genetic alterations. Immunohistochemistry (IHC) provided spatial protein expression data to validate the presence of specific biomarkers across tissue samples. Single-cell Ribonucleic Acid (RNA) sequencing of core needle biopsies from patients and preclinical models allowed for high-resolution transcriptomic profiling of the tumor microenvironment. Computational analysis of these sequencing datasets enabled the clustering of tumors based on their transcriptional signatures and the identification of subtype-defining transcription factors. Preclinical testing involved the evaluation of pharmacological inhibitors targeting Mitogen-activated protein kinase (MEK) and AXL receptor tyrosine kinase. The investigators also developed and tested novel chimeric antigen receptor (CAR) T-cells engineered to target AXL, Delta-like ligand 3 (DLL3), and CD56 in various experimental settings. Statistical frameworks were applied to correlate the expression of Yes-associated protein 1 with specific mutational landscapes and therapeutic outcomes in both in vitro and in vivo models.

Analysis revealed that the presence or absence of Yes-associated protein 1 (YAP1) effectively partitions large cell neuroendocrine carcinoma into two distinct biological subsets. The YAP1-high group exhibited a mesenchymal phenotype and an inflamed immune microenvironment, frequently harboring co-occurring mutations in CDKN2A/B and SMARCA4 alongside TP53. Pharmacological screening showed that these YAP1-high tumors are particularly sensitive to MEK and AXL inhibition, as well as AXL-directed chimeric antigen receptor T-cell therapy. Conversely, the YAP1-low subset displayed epithelial characteristics and an immune-cold profile, with a high prevalence of TP53 and RB1 co-mutations. This YAP1-low group expressed transcription factors such as Achaete-scute homolog 1 (ASCL1) and Neuronal differentiation 1 (NEUROD1), mirroring the molecular landscape of small cell lung cancer. Therapeutic testing in the YAP1-low models demonstrated significant sensitivity to DNA damage repair inhibition and cellular therapies targeting DLL3 and CD56. These findings confirm that YAP1 status is a reliable indicator of both the underlying oncogenic drivers and the potential efficacy of subtype-specific treatments.

The findings establish that YAP1 status serves as a primary molecular determinant of the identity of large cell neuroendocrine carcinoma. Distinct biological pathways drive the progression of these subtypes, suggesting that a one-size-fits-all treatment approach is likely suboptimal for this patient population. The identification of specific genetic co-alterations provides a roadmap for selecting patients who may benefit from targeted inhibitors or novel immunotherapies. These results support the clinical development of AXL, DLL3, and CD56-targeted chimeric antigen receptor T-cells as precision medicine tools. Future clinical trials should incorporate YAP1 expression as a stratification factor to improve the efficacy of therapeutic interventions. This research provides a necessary foundation for shifting the management of this malignancy toward a biomarker-driven paradigm similar to other lung cancers. Ultimately, the study suggests that molecular subtyping can transform the prognosis of patients by matching them with therapies that exploit their tumor's specific biological weaknesses.